Extrahepatic Delivery Of mRNA-LNP To Spleen: Towards In Vivo CAR Therapeutics

By Kalyan Golla, Sams Sadat, Hossein Yazdani Ahmadabadi, Karolin Kolengaden Paulson, Malathi Anantha, Ruchi Sharma, Benny Chan, Helena Son, Avisek Deyati, Tony Wu, Zhengyu Chen, Deo Prakash Tiwari, Jeffrey Lam, Jeff Emmanuel, Angela Zhang, Gemma Ryan, Nikita Jain, Jay Paquette, Samuel Clarke, and Anitha Thomas

In vivo CAR-T therapy is reshaping how cell therapies could be developed and delivered, shifting from complex, multi-step manufacturing toward a streamlined, in-body approach. Lipid nanoparticle (LNP) systems are emerging as a key enabler, allowing genetic material to reach and reprogram T cells directly within the patient. Advances in LNP design are improving delivery beyond the liver, with promising targeting of lymphoid organs like the spleen, where immune activity is concentrated. Enhanced specificity across splenic cell types, including T cells, points to new possibilities for efficient, scalable immunotherapy. By removing the need for cell extraction and reinfusion, this approach could reduce timelines and broaden patient access.

Explore how these innovations are helping move in vivo cell engineering closer to reality.